Trumenba is a vaccine designed to protect against Neisseria meningitidis serogroup B, a bacteria that can cause serious infections like meningitis. It is recommended for adolescents and young adults, particularly those aged 16 to 23, as they are at higher risk for this type of meningococcal disease. The vaccine is administered in two doses, typically given at least six months apart. Common side effects may include pain at the injection site, fatigue, and headache. Trumenba is part of a broader strategy to prevent meningococcal disease, which can lead to severe health complications or even death.